RX-0301 is under clinical development by Zhejiang Haichang Biotechnology and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RX-0301’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RX-0301 is under development for treatment of hepatocellular carcinoma. It is a nano-liposomal formulation of RX-0201. The drug candidate targets Akt-1 and is developed based on QTsome technology.
Zhejiang Haichang Biotechnology overview
Zhejiang Haichang Biotechnology is a biotechnology company headquartered in China. The company is engaged in the manufacture and development of complex intravenous pharmaceutical products for the treatment of cancer related diseases
For a complete picture of RX-0301’s drug-specific PTSR and LoA scores, buy the report here.